Arca
Skip to content
Tools
Tools

Nonalcoholic steatohepatitis (NASH)

Drug research and approvals for nonalcoholic steatohepatitis (NASH): what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 198 studies of nonalcoholic steatohepatitis (NASH) are recruiting on ClinicalTrials.gov, and Health Canada has authorized 44 drug trials for it since 2013.

  • Recruiting worldwide: 198
  • Trials authorized in Canada: 44
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting now

Newest posted first, of 198 recruiting on ClinicalTrials.gov ↗

Trials authorized in Canada

The 10 newest of 44; search them all in Canada trials
Apr 9, 2026Phase 2, randomized, double-blind, placebo-controlled study to evaluate MGL-3196 (resmetirom) in patients with MASH who have undergone liver transplant for…Resmetirom (MGL-3196)Madrigal PharmaceuticalsPending
Aug 26, 2024A randomised, double-blind, placebo-controlled, multicentre, phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult…Survodutide (bi 456906)Boehringer Ingelheim PharmaceuticalsOngoing
Aug 26, 2024A phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in…Survodutide (bi 456906)Boehringer Ingelheim PharmaceuticalsOngoing
Jul 5, 2024A phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of efruxifermin in subjects with compensated cirrhosis due to…EfruxiferminAkero TherapeuticsOngoing
Aug 17, 2023A phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of efruxifermin in subjects with non-cirrhotic nonalcoholic…Efruxifermin (EFX)Akero TherapeuticsOngoing
May 30, 2023A phase 2b randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of efinopegdutide (MK-6024) in adults with…Efinopegdutide (MK-6024) / Wegovy (semaglutide)Merck & Co. (MSD)Ongoing
Feb 23, 2023A randomized double-blind placebo-controlled phase 3 study to evaluate the effect of resmetirom on liver-related outcomes in patients with well-compensated…Resmetirom (MGL-3196)Madrigal PharmaceuticalsOngoing
Feb 17, 2023Investigation of pharmacokinetics following administration of NNC0194-0499 and semaglutide as co-formulation versus separate injections in healthy participantsNNC0194-0499 b / Semaglutide b / NNC0194-0499 semaglutide aNovo NordiskClosed
Nov 30, 202217b-hydroxysteroid dehydrogenase type 13 minimization for the treatment of NASH (HORIZON): a double-blind, placebo-controlled phase 2b study to evaluate the…GSK4532990GSKClosed
Apr 7, 2022A phase 2, multicenter, placebo-controlled, randomized, double-blind, 48-week study to evaluate the efficacy and safety of combination therapy of K-877-er and…Pemafibrate (K-877) / Tofogliflozin (CSG452)Kowa Research Institute, IncClosed

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.